Karyopharm Therapeutics Investor Presentation — February 2020

Document content

February 2020Corporate Presentation2 ©2020 Karyopharm Therapeutics Inc. This presentation contains forward- looking statements within themeaning ofthe“safe harbor” provisions ofThe Private Securities Litigation Reform Actof1995 .Such forward-

looking statements include those regarding Karyopharm’s expectations relating toXPOVIO®forthetreatment ofpatients with heavily pretreated multiple myeloma, thetherapeutic

potential ofandpotential clinical development plans andcommercialization forKaryopharm’s drug candidates, including thetiming ofinitiation ofcertain trials, ofthereporting of

data from such trials, ofthesubmissions toregulatory authorities andofpotential commercial launches ;thepotential availability ofaccelerated approval pathways ;thepotential size

ofthemarkets formultiple myeloma drugs andmultiple myeloma drugs fortreatment ofpatients withrelapsed multiple myeloma ;thepotential sizeofthemarkets fordiffuse large B-

celllymphoma (DLBCL) drugs andDLBCL drugs fortreatment ofpatients withrelapsed and/orrefractory DLBCL ;andKaryopharm’s strategic andfinancial plans andexpectations

aswellasfinancial projections forKaryopharm .Such statements aresubject tonumerous important factors, risks anduncertainties thatmay cause actual events orresults todiffer

materially from Karyopharm’s current expectations .Forexample, there canbenoguarantee thatKaryopharm willsuccessfully commercialize XPOVIO, thatregulators willagree

thatselinexor qualifies forconditional approval intheE.U.asaresult ofthedata from theSTORM study inpatients with penta -refractory myeloma oraccelerated approval inthe

U.S.based ontheSADAL study inpatients with relapsed/refractory DLBCL orthat any ofKaryopharm’s drug candidates, including selinexor and eltanexor (KPT -8602),